TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06706310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active substance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQA3334 Tablet
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQA3334 Tablet
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQA3334 Tablet
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleoside (acid) analogs (NAs)
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleoside (acid) analogs (NAs)
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleoside (acid) analogs (NAs)
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleoside (acid) analogs (NAs)
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleoside (acid) analogs (NAs)
Description: Inhibit viral replication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleoside (acid) analogs (NAs)
Description: Inhibit viral replication.
Study: NCT06714955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Description: Drug: BGM0504 Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
Description: Drug: BGM0504 Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Description: Drug: Placebo Administered SC
Study: NCT06718634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M08D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05829460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUD (Progestin)
Description: Released via the levonorgestrel-releasing IUD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUD (Progestin)
Description: Released via the levonorgestrel-releasing IUD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine behavioral weight program
Description: Optional to attend.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine behavioral weight program
Description: Optional to attend.
Study: NCT06724523

Intervention type: BEHAVIORAL
Intervention: Business-as-usual instruction
Description: Deaf children are receiving business-as-usual instruction in sign language in deaf education programs.
Study: NCT06722326

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Hydrogen-rich water
Description: Hydrogen-rich water with 12 mg of hydrogen per serving

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: Control water
Description: Control water with 0 mg of hydrogen per serving
Study: NCT06724614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDPHL01
Description: VDPHL01 Extended Release (ER) Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDPHL01
Description: VDPHL01 Extended Release (ER) Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06731166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care
Description: Videomonitoring provide by cardiovascular nurses
Study: NCT06722560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 hormone
Description: s.c. continuous infusion for 72 hours using an insulin pump

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s.c. continuous infusion for 72 hours using an insulin pump
Study: NCT06743516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy with external stent
Description: Inserting ureteric stent at the pancreaticojejunostomy site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy without external stent
Description: Only Pancreaticojejunostomy without inserting external stent
Study: NCT06744127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-1
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-2
Description: One tablet administered alone
Study: NCT06744231

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Prior to implementation of the Thriving Hearts package of services, people living in participating counties will receive usual care for pregnancy, birth, and postpartum services. The study team will quantify existing services using a study-developed usual care assessment instrument.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thriving Hearts
Description: Thriving Hearts is a collaboration among LHDs in ten North Carolina counties. At the individual level, pregnant individuals will self-screen for HDP risk during prenatal visits, and those at risk will be provided a Mama Hearts Care Kit, including a home blood pressure monitor, low dose aspirin, and culturally tailored educational materials.~At the healthcare provider level, burnout and compassion fatigue will be addressed through skill-building activities, including training in the Community Resilience and Mindfulness-Based Stress Reduction.~At the community level, Loving Connection will provide proactive material and social support through Community Health Workers, text messaging-based communication, a medical legal partnership, and capacity-building support for community-based organizations.
Study: NCT06740968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: During each of the 5 visits, participants will be seated in a comfortable position and a cap will be placed on participant's head similar to a swimming cap. Small electrodes will be placed near the surface of the scalp at certain regions of interest, and a weak electrical current will be passed through the electrodes into speech related brain areas for 20 minutes. The study team will not use current strengths exceeding 2 milliamps (mA).
Study: NCT06720727

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: craniospinal irradiation
Description: Delivering radiotherapy to brain, spinal cord and its covering membrane.
Study: NCT06751069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Pulmonary Rehab
Description: Participants are expected to engage in the home-based PR routine five to six days a week for the entire 12-week study period. The PR routine begins with slow upper body and timed breathing exercises, followed by two slow balance walks for 6 minutes each. The total exercise time is 24 minutes a day followed by a 4-minute mindful breathing meditation/cool down. Exercises may be modified or repeated according to baseline activity level and as conditioning improves.
Study: NCT06747390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: 1% lidocaine will be injected under direct visualization (not exceeding the maximum tolerated dose of 4.5 mg/kg body weight) into the primary tumor with the aim to distribute the lidocaine evenly into the tumor.
Study: NCT06742710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide and metformin
Description: Liraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1500 mg/day until pregnancy
Study: NCT06756295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: individualized tumor FAST vaccine combination (including adjuvant)
Description: Using the patient's individual tumor tissue, an autologous FAST (Fragmented Autoantigen Stimulated T-cell Immunotherapy) vaccine is prepared.
Study: NCT06756074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)
Description: pancreaticojejunostomy was done with application of glubran 2: The blister pack was opened, and the sterile single-dose vial was released directly onto the operating table in a sterile environment, Draw the Glubran 2 out of the single-dose vial using a sterile syringe then put the syringe into applicator Glubran 2 was applied into anastomosis by applicator in spraying manner . Whenever possible, the area to be treated should be cleaned before application. When applied in such a minimal amount, once it had polymerized, Glubran 2 formed a thin adhesive layer. It was therefore essential not to apply more than one drop in the same point. A second layer of Glubran 2 may not be applied until the first had polymerized. Any excess product was removed using a dry swab within 5-6 seconds after application. Glubran 2 was not touched after application until the polymerization reaction is complete, as it may detach or not produce the desired effect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
Description: Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
Study: NCT06132256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Administered as intravenous (IV) infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
Study: NCT06747858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-032
Description: CFTR mRNA formulated in lipid nanoparticles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-032
Description: CFTR mRNA formulated in lipid nanoparticles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-032
Description: CFTR mRNA formulated in lipid nanoparticles
Study: NCT06759935

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser therapy
Description: sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy/exercise protocol
Description: physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes Codman's pendulum exercise, range of motion (ROM) exercises, stretching and isometric strengthening exercises, for 4 consecutive weeks with a minimum of 3 sessions per week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: physiotherapy/exercise protocol
Description: physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes Codman's pendulum exercise, range of motion (ROM) exercises, stretching and isometric strengthening exercises, for 4 consecutive weeks with a minimum of 3 sessions per week.
Study: NCT06761092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Dexmedetomidine for Post-Anesthesia Delirium in Preschool Children
Description: Nebulization with the anesthetic drug dexmedetomidine at a dose of 2 mcg/kg body weight, diluted to 3 ml with 0.9% normal saline, administered before the induction of anesthesia in the reception area.~After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 0.9% Normal Saline
Description: Nebulization with normal saline 0.9% 3 ml, administered before the induction of anesthesia in the reception area. After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room
Study: NCT06761716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ericksonian Hypnotherapy
Description: Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will focus on tailored hypnotic suggestions, subconscious communication techniques, and trauma-focused interventions specifically designed to address PTSD symptoms. Sessions will be conducted by a certified hypnotherapist under clinical supervision.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will utilize cognitive restructuring techniques, exposure exercises, and behavioral interventions aimed at reducing PTSD symptoms. Sessions will be led by a licensed psychotherapist trained in trauma-focused CBT.
Study: NCT06753136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous, laparoscopic or laparotomy lesion electrochemotherapy
Description: All patients will receive Bleomycin intravenously with a dosage of 15.000 IU/m2. After a drug distribution time of 8 minutes, the lesions will be electroporated using the Cliniporator (IGEA S.P.A., Carpi, Italy), applying special handpieces depending on the route used: laparoscopic electrode, flexible and expandable for the laparoscopic procedure, linear or hexagonal electrode for laparotomy surgical access, variable geometry electrode for percutaneous access. The ECT procedure must be completed within 40 minutes.
Study: NCT06752694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT05837286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oval-8 ® Orthosis
Description: The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone injection only
Description: The control group will receive a cortisone injection and be instructed to move their fingers normally
Study: NCT06752694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT06755125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Patients in Group A will be treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with kinesio taping. Kinesio tape will be applied directly to the muscle with 50% stretching.During the treatment, kinesio tape will be applied to the patients twice a week, eight times in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Patients in Group B will be treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with dry needling.During the treatment, dry needling will be applied to the patients twice a week, eight times in total.
Study: NCT06754540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Azacitidine 32mg/m2
Study: NCT06767007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will begin SBRT treatment within 2 weeks after the first round of chemotherapy. Intensity-modulated radiation therapy (IMRT) technology will be used, with a target gross tumor volume (GTV) of 5-8Gy/5 sessions, a total dose of 25-40Gy equivalent to a biological effective dose (BED) of 37.5-72Gy, administered from Monday to Friday. For patients who have previously received pelvic radiotherapy, the re-irradiation dose will be 3-5Gy/5 sessions, a total dose of 15-25Gy equivalent to a BED of 19.5-37.5Gy, administered from Monday to Friday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1
Description: The PD-1 monoclonal antibody used is Sintilimab 200mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: First-line chemotherapy regimen of rectal cancer, using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy
Study: NCT06763263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Children and their parents in this group will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. Then, the child will be allowed to choose one of the superhero clothes he/she wants in his/her room and will be allowed to wear the clothes. The superhero figure will be shown to him/her and he/she will be allowed to play with the clothes and the figure for 2 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The children in this group and their parents will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. The children will be evaluated in terms of their reactions after their hospitalization, they will not be dressed in any clothing and no superhero figures will be used. Then the questionnaire will be filled out again and scoring will be done. In order to prevent ethical bias before discharge, the child will be dressed in a superhero costume and will be allowed to spend time with the clothing and figure.
Study: NCT06763718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Qigong Breathing Exercise
Description: The exercise is recommended to be performed standing, or modified standing with trunk leaning forward and bilateral upper extremities support on countertop. Initial position: Stand up with feet shoulder-width apart, hands down along the body, or put palms on the abdomen. Take a deep breath, squaring shoulders, and pull in belly at the same time. Hold breath for 3 to 4 seconds, while keeping abdomen retracted with maximally contracting abdominal muscles. Exhale, so the shoulders go back to the starting position, while chest and abdominal muscles relax. Repeat this exercise 10 times. Note. If the stomach is difficult to draw in a standing position, it is possible to perform the exercise with both hands resting on support.~Duration: 30 minutes, 3 days/ week for 8 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No exercise will be given to the participants in the control group
Study: NCT06763146

Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY948862)
Description: Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.
Study: NCT06764160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Participants will receive Eculizumab via intravenous (IV) infusion.
Study: NCT06767059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Group
Description: Patients will be asked to walk for 30 minutes at least 3 times for 8 weeks. In order to ensure regular follow-up, patients will be asked to write on the walking tracking form when they walk and the number of steps before they start walking and the number of steps after walking using the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grounding Group
Description: Patients will be asked to walk with a grounding stick for 30 minutes at least 3 times for 8 weeks. Patients will be asked to fill in the walking follow-up form and grounding follow-up form for regular follow-up.